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Introduction
Methylmalonic aciduria may occur as a result ofa block in the conversion of methylmalonyl coenzyme A (CoA) to succinyl CoA. Such a deficiency arises from either a defect in methylmalonyl CoA mutase (MCM),' the mitochondrial homodi- 1 . Abbreviations used in this paper: AdoCbl, 5'-deoxyadenosylcobalamin; CN-Cbl, cyanocobalamin; Cbl, cobalamin or vitamin B12; CRM, cross-reacting material; OH-Cbl, hydroxocobalamin; MCM, methylmalonyl CoA mutase; MUT, locus encoding the gene for methylmalonyl CoA mutase; PCR, polymerase chain reaction. meric enzyme that catalyses the reaction, or a defect in the pathway for the synthesis of 5'-deoxyadenosylcobalamin (AdoCbl), the Cbl-derived cofactor required by the MCM apoenzyme. Genetic complementation analysis of cultured fibroblasts from patients with methylmalonic aciduria without homocystinuria has defined three complementation classes that reflect the clinical response to Cbl supplementation: mut, which has a defective MCM apoenzyme; and cblA and cblB, which represent defects in the intramitochondrial synthesis of AdoCbl cofactor.
The mut class is divided into two subclasses: mut-lines have a MCM enzyme with detectable activity but exhibiting a greatly reduced affinity for the AdoCbl cofactor; mut0 lines show no detectable MCM activity even if AdoCbl is provided in excess. These two subclasses have never been observed to complement each another, suggesting that the mutations occur at the MUT locus (1) . The recent cloning and sequencing of human MCM (2, 3) has enabled molecular characterization of mutations at this locus underlying the various phenotypes (4) (5) (6) .
This investigation involved a primary fibroblast line, designated WG 1130, obtained by skin biopsy from a patient with neonatal methylmalonic aciduria without homocystinuria who died at the age of 5 mo. The line exhibited a marked decrease in propionate (a precursor of methylmalonyl CoA) incorporation that was unresponsive to Cbl supplementation, suggesting a mutation in the MCM apoenzyme. Total Cbl distribution was within normal limits, also indicating a defect in the MCM apoenzyme.
To confirm the diagnosis of WGl 130 as a member of the mut complementation class, cell-fusion complementation analysis was performed with WG 1 130 against a series of cultured fibroblast lines representing the cb/A, cblB, and mut complementation classes. As expected, WG 1 130 complemented with the cblA and cblB cell lines. However, complementation was also observed with four out of five mut-lines and three out of nine mut" lines. Such findings strongly suggest the possibility of interallelic complementation. All strains were determined to be free of mycoplasma contamination. Cultures were maintained in Eagle's minimum essential medium with nonessential amino acids supplemented with 10% (vol/vol) fetal bovine serum. Cbl uptake and distribution and the whole cell incorporation of ['4Cjmethyltetrahydrofolate and ['4C] propionate were determined as previously described (9) .
Cellfusion. Equal numbers of cells from two lines were mixed and plated into tissue culture dishes. 24 h after plating, one half of the cultures were exposed for 60 s to a 40% solution of polyethylene glycol 1000 in phosphate-buffered saline to induce cell fusion. After an additional 24 h, medium was replaced with Puck's F medium supplemented with 15% fetal bovine serum and 100 jM [I-'4Cjpropionate (to give a specific activity of 10 ,Ci/umol) and reincubated for 18 h. At the end of this period propionate incorporation was calculated as above (9) . To determine whether complementation had occurred the incorporation ofpropionate from fused and unfused replicates were compared.
Cloning and expression ofMCM cDNA. Total RNA was prepared from confluent fibroblasts and MCM cDNA was generated by primer extension and polymerase chain reaction (PCR) amplification as described (5, 6). The cDNA was amplified and subcloned into the vector pGEM7zf(+) (Promega Biotec, Madison, WI). Double-stranded dideoxy sequencing was performed using T7 polymerase (Pharmacia, Inc., Piscataway, NJ) with T7 (Promega Q501 1), SP6 (Promega Q512 1), or MCM-specific primers described in (6) . The sequence of a clonal isolate ofthe MCM cDNA was compared to the sequence from a pool of 15 independent clones to distinguish authentic heterozygous or homozygous mutations from artifacts introduced by PCR.
Expression of recombinant MCM. A vector which expresses the normal consensus human MCM cDNA using the cytomegalovirus immediate early promoter in the vector pNAss-CMV (10) has been described (1 1). A clone containing the WG 1130 mutation was constructed by PCR amplification of a region from the mutant cDNA spanning the MspI site, the mutation site, and the KpnI site, and recombining the MspI/KpnI fragment ofthis material with NotI/MspI, KpnI/ NsiI, and NsiI/SalI fragments in the NotI/SalI-digested vector pNAss-CMV by sequential multipart ligations. The reconstitution of ligated sites was confirmed by restriction mapping and sequences generated by PCR were confirmed by sequencing. Clones were introduced via electroporation (12) into a muto primary fibroblast cell line GM 1673 (National Institute of General Medical Services Mutant Cell Repository). Electroporation was performed using a Gene Pulser (BioRad Laboratories, Richmond, CA) after a 5-min preincubation of0.6 ml ofcells at a density of 3 X 106/ml with 20 Ag of DNA using voltage pulses of 260 V at a capacitance of 960 ,F. MCM activity was assayed 2 d after electroporation using a modified propionate incorporation assay which uses [3H]leucine incorporation to normalize for cell number and constitutive protein synthesis (4 (Table II) .
Cloning and expression ofMCM cDNAfrom WG1130. The MCM cDNA from WG 1130 was sequenced and a single homozygous mutation (G354 -a A; Arg93 --His) was identified (Fig. 1 A) .
In order to determine whether this sequence change was responsible for the phenotype of the WG1130 cells, a MspI/ KpnI fragment containing this mutation was substituted into the expression vector containing the functional consensus MCM cDNA (pCMV-hMCM) to create the clone pCMV 1 130 (Fig. I B) Complementation between two mut cell lines has never previously been described. In fact, the singular nature of the MUT locus encoding the MCM apoenzyme was demonstrated by the presence ofa discrete mut complementation group. This inference has been confirmed by molecular genetic studies which identified a single chromosomal locus (MUT) gene encoding the subunit of the MCM homodimer (13, 14 evidence of propionate incorporation under any conditions were designated mut0, whereas mutant cell lines in which propionate incorporation could be stimulated with Cbl were designated mut-. The enzyme in at least some mut-cell lines has been shown to have a markedly elevated Krnzobakin) (1) . Subsequent work by Kolhouse et al. (7) showed that all mut-cell lines showed immunochemically CRM to MCM antibody, whereas some muto lines showed CRM and others did not. 
